Overview

Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether scopolamine-induced cognitive impairment is attenuated by the administration of roflumilast in combination with donepezil.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Takeda
Treatments:
Butylscopolammonium Bromide
Donepezil
Scopolamine
Scopolamine Hydrobromide